MX2017016835A - Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios. - Google Patents

Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios.

Info

Publication number
MX2017016835A
MX2017016835A MX2017016835A MX2017016835A MX2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A
Authority
MX
Mexico
Prior art keywords
methods
individual
treating autoimmune
alloimmune
present disclosure
Prior art date
Application number
MX2017016835A
Other languages
English (en)
Spanish (es)
Inventor
Panicker Sandip
Parry Graham
A Nikitin Pavel
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of MX2017016835A publication Critical patent/MX2017016835A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017016835A 2015-06-26 2016-06-23 Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios. MX2017016835A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26
PCT/US2016/039087 WO2016210172A1 (en) 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders

Publications (1)

Publication Number Publication Date
MX2017016835A true MX2017016835A (es) 2018-08-01

Family

ID=57585852

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016835A MX2017016835A (es) 2015-06-26 2016-06-23 Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios.
MX2023002021A MX2023002021A (es) 2015-06-26 2017-12-19 Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002021A MX2023002021A (es) 2015-06-26 2017-12-19 Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.

Country Status (12)

Country Link
US (3) US20180169240A1 (https=)
EP (1) EP3313417A4 (https=)
JP (1) JP6963509B2 (https=)
KR (1) KR20180020296A (https=)
CN (1) CN108348600A (https=)
AU (2) AU2016282782A1 (https=)
CA (1) CA2990662A1 (https=)
EA (1) EA038567B1 (https=)
HK (1) HK1254030A1 (https=)
IL (1) IL256424B2 (https=)
MX (2) MX2017016835A (https=)
WO (1) WO2016210172A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
WO2016164358A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
AU2017258492B2 (en) 2016-04-29 2023-12-07 Pfizer Inc. Interferon beta antibodies and uses thereof
HUE073475T2 (hu) 2016-10-12 2026-01-28 Bioverativ Usa Inc C1s elleni antitestek és alkalmazási eljárásaik
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
MX2021013441A (es) 2019-05-15 2021-12-10 Chugai Pharmaceutical Co Ltd Molecula de union a antigenos, composicion farmaceutica y metodo.
TWI856193B (zh) * 2019-10-16 2024-09-21 日商中外製藥股份有限公司 抗體、醫藥組成物及方法
IL300376A (en) * 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
WO2004022096A1 (en) * 2002-09-06 2004-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
WO2009132058A2 (en) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
CN104870475B (zh) * 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf

Also Published As

Publication number Publication date
JP6963509B2 (ja) 2021-11-10
IL256424B2 (en) 2024-09-01
AU2022215307A1 (en) 2022-09-08
CA2990662A1 (en) 2016-12-29
US20180169240A1 (en) 2018-06-21
EA038567B1 (ru) 2021-09-15
IL256424A (en) 2018-02-28
EA201890106A1 (ru) 2018-05-31
BR112017027578A2 (pt) 2018-08-28
HK1254030A1 (zh) 2019-07-12
IL256424B1 (en) 2024-05-01
MX2023002021A (es) 2023-03-15
US20220249664A1 (en) 2022-08-11
US20250295768A1 (en) 2025-09-25
EP3313417A1 (en) 2018-05-02
AU2016282782A1 (en) 2018-01-18
WO2016210172A1 (en) 2016-12-29
EP3313417A4 (en) 2019-06-12
JP2018526330A (ja) 2018-09-13
CN108348600A (zh) 2018-07-31
NZ738570A (en) 2025-05-02
KR20180020296A (ko) 2018-02-27
AU2022215307B2 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
MX2023002021A (es) Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.
MX2015015764A (es) Lente oftálmica con sistema microfluídico.
WO2016073380A8 (en) Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
MX2017015758A (es) Componente de dispositivo, dispositivo, y metodo para purificar y ensayar biomoleculas de muestras biologicas.
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
PH12017502222B1 (en) Lag-3-binding molecules and methods of use thereof
EP2959280A4 (en) METHOD FOR LANGUAGE DECODING OF THE BRAIN AND SYSTEMS FOR CARRYING OUT THEREOF
MX2017001138A (es) Metodo.
WO2013142796A3 (en) Methods of treatments using ctla4 antibodies
MX2015017807A (es) Sistema cerrado integrado de extraccion de linea intravenosa.
HK1250752A1 (zh) 治疗骨髓增生性障碍的方法
MX2013012284A (es) Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
ZA201800498B (en) Anti¿pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
BR112015017403A2 (pt) biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
EP3452825A4 (en) SYSTEM AND METHOD FOR DIFFERENTIATING BLOOD COMPONENTS
EA201691647A1 (ru) Способы кратковременного и долгосрочного лечения зависимости от лекарственных средств
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
EP4465017A3 (en) System for determining the amount of hemoglobin in a plasma fraction
EP3297703A4 (en) PHOTOTHERAPY SYSTEM AND METHOD FOR PREVENTING OR TREATING CARBON MONOXIDE POISONING
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
EA201691168A1 (ru) Способы исследования бета-глюкана
EA201891693A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови
IN2014MN01795A (https=)